Analysts forecast that NeuBase Therapeutics (NASDAQ:NBSE) will announce earnings per share of ($0.20) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for NeuBase Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.20). The company is scheduled to issue its next quarterly earnings report on Thursday, November 12th.
On average, analysts expect that NeuBase Therapeutics will report full year earnings of ($0.90) per share for the current year, with EPS estimates ranging from ($0.94) to ($0.88). For the next financial year, analysts expect that the business will report earnings of ($1.05) per share, with EPS estimates ranging from ($1.22) to ($0.91). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover NeuBase Therapeutics.
NeuBase Therapeutics (NASDAQ:NBSE) last posted its earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05.
NBSE has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of NeuBase Therapeutics in a research report on Tuesday, May 19th. Chardan Capital reaffirmed a “buy” rating on shares of NeuBase Therapeutics in a research report on Friday, August 14th. Royal Bank of Canada reissued a “buy” rating and issued a $16.00 price target on shares of NeuBase Therapeutics in a report on Sunday, August 16th. Zacks Investment Research downgraded shares of NeuBase Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 21st. Finally, BidaskClub upgraded shares of NeuBase Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. NeuBase Therapeutics currently has a consensus rating of “Buy” and an average price target of $14.71.
Several hedge funds and other institutional investors have recently bought and sold shares of NBSE. Nuveen Asset Management LLC purchased a new position in shares of NeuBase Therapeutics in the 2nd quarter worth about $890,000. Oak Grove Capital LLC purchased a new position in shares of NeuBase Therapeutics in the second quarter valued at about $246,000. Charles Schwab Investment Management Inc. purchased a new position in NeuBase Therapeutics during the 2nd quarter valued at about $382,000. Bank of America Corp DE raised its holdings in shares of NeuBase Therapeutics by 206.2% during the second quarter. Bank of America Corp DE now owns 27,913 shares of the company’s stock valued at $245,000 after acquiring an additional 18,798 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in NeuBase Therapeutics in the 2nd quarter worth $120,000. 25.39% of the stock is owned by institutional investors.
NBSE stock traded up $0.27 during midday trading on Tuesday, reaching $7.91. 267,400 shares of the company’s stock traded hands, compared to its average volume of 141,311. NeuBase Therapeutics has a fifty-two week low of $4.15 and a fifty-two week high of $11.78. The business has a 50-day moving average price of $8.00 and a two-hundred day moving average price of $7.86.
About NeuBase Therapeutics
NeuBase Therapeutics, Inc, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders.
Featured Story: Most Volatile Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.